صدى البلد: مات مسموما بالزرنيخ تعرف على قصة حياة العالم ربورت بنزن elbalad.news - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from elbalad.news Daily Mail and Mail on Sunday newspapers.
(1)
NIJMEGEN, Netherlands, Jan. 28, 2021 /PRNewswire/
To take AI development in pathology to the next level, a European consortium combining leading European research centres, hospitals as well as major pharmaceutical industries, is going to develop a repository for the sharing of pathology data. The 6-year, €70 million project called BIGPICTURE, will herald a new era in pathology.
Background: Sectra contributes to accelerate AI innovation for diagnostics in digital pathology
Sectra engages in the new EU Innovative Medicines Initiative project BIGPICTURE to construct a large-scale database of pathology images. Sectra s contributions will help accelerate the development of improved diagnostic methods based on artificial intelligence, supporting an effective interplay between healthcare and academic research. The Sectra efforts include a close collaboration with the BIGPICTURE partners Center for Medical Image Science and Visualization (CMIV) at Linköping University and Regio
E-Mail
A new consortium of the EU Innovative Medicines Initiative (IMI) aims to establish the biggest database of pathology images to accelerate the development of artificial intelligence in medicine.
To take AI development in pathology to the next level, a European consortium combining leading European research centres, hospitals as well as major pharmaceutical industries, is going to develop a repository for the sharing of pathology data. The 6-year, €70 million project called BIGPICTURE, will herald a new era in pathology.
Pathology is the cornerstone of the workup of many diseases such as cancer, autoimmune diseases, of the follow up after transplantation and is also critical for the evaluation of the safety of drugs. It s based on the examination of tissue samples (slides) under the microscope. However, despite its pivotal role, it still relies heavily on the qualitative interpretation by a qualified pathologist.
New SARS-CoV-2 neutralizing antibody enters clinical phase 7thspace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 7thspace.com Daily Mail and Mail on Sunday newspapers.
Boehringer Ingelheim: New SARS-CoV-2 Neutralizing Antibody enters Clinical Phase
Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim collaborate on potential COVID-19 therapy and prevention
BI 767551 (DZIF-10c) is a potent anti-SARS-CoV-2 antibody that has shown promising virus neutralizing properties in pre-clinical research
Phase 1/2a clinical trials will evaluate the safety, pharmacokinetics, and antiviral activity of BI 767551 administered by intravenous infusion and by inhalation. The first patients have already been enrolled
Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investigation of BI 767551, a new SARS-CoV-2 neutralizing antibody. By combining UKK, UMR and DZIF s expertise in virology, immunology and clinical investigation with Boehringer